LifeMine Therapeutics announced a $263M raise today to help accelerate the development of its novel calcineurin activation inhibitor that aims to radically change the profile of organ transplants
Co-Founder, President & CEO Greg Verdine describes the toxicity issues associated with the immuosupressive drugs that transplant recipients currently receive, and explains how LIFE-001 is different. Plus, given how the therapy is designed to safely prevent T-cell activation and proliferation, there could also ultimately be an autoimmune use case as well.
2 days ago
Biotech CEO Sisterhood: Amy Burroughs discusses the success of Terns Pharma and developing TERN-701 for CML, being acquired by Merck for $6.7 billion, and leadership learnings throughout her career
Interviewed by Sisterhood editorial board member Erika Smith, Amy Burroughs discusses joining Terns when it was not obvious and at a time when the company was going through a sad moment, and how the momentum started to turn as data for TERN-701 started becoming apparent. She describes her career, which included stops at large and small companies, and on the investing side at 5AM Ventures, and provides leadership lessons along the way. Biographies Amy Burroughs is a biopharmac
2 days ago
Biotech's movers for the week of July 27th and a preview of the week ahead
A couple of big clinical trial failures weighed on biotech this week, while two FDA AdComm meetings (one positive and one negative) were in the news. Watch for a couple of high profile FDA decisions that are scheduled for next week.
7 days ago
.png){kind=logo}